Objectives: This study aims to compare the beta-2 adrenergic receptor (ADRB2) gene polymorphisms of patients with fibromyalgia syndrome (FMS) with those of healthy control subjects, and to investigate the possible relationship between symptoms of FMS and polymorphisms of the ADRB2 gene. Patients and methods: The study included 170 females (mean age 47.8±10.3 years; range, 21 to 75 years) diagnosed with FMS according to the 2010 American College of Rheumatology criteria and 170 healthy females (mean age 47.2±8.8 years; range, 20 to 72 years) as the control group. Several clinical symptoms of the participants related to FMS were questioned and recorded. The visual analog scale (VAS) and Fibromyalgia Impact Questionnaire (FIQ) scores of the fibromyalgia group were recorded. In both groups, the ADRB2 (rs1042717) single-nucleotide polymorphism was detected by way of a real-time polymerase chain reaction. The wild-type (Guanine/Guanine), the mutant type (Adenine/Adenine) and heterozygous type (Adenine/Guanine) were detected. The sample power was calculated considering the minor allele frequency. Results: The comparison of the ADRB2 gene polymorphism between patients with FMS and the control subjects showed that the groups were similar in terms of ADBR2 gene polymorphism and genotype (p>0.05). There was no significant difference in terms of genotype when the ADRB2 gene polymorphisms in patients with FMS were compared in terms of clinical symptoms, VAS and FIQ scores (p>0.05). Conclusion: Beta-2 adrenergic receptor (rs1042717) gene polymorphisms and genotype distribution are no different between patients with FMS and healthy individuals. ADRB2 gene polymorphisms in patients with FMS have no effect on clinical symptoms and VAS and FIQ scores. The results of the present study will light the way for future research into ADRB2 gene polymorphisms in the pathogenesis of FMS.

We herein report the determination of the cytotoxic activity and expression profiles of some DNA repair genes of newly synthesized azomethines in the gastric cancer cell line (AGS). The studied novel compounds were synthesized by a condensation reaction and received compounds were characterized by ¹H and ¹³C NMR spectroscopy methods. Furthermore, they were applied to the AGS cell line at eight different concentrations (0.1–50 µg/mL). Anticancer activities were determined using the MTT method. Expression levels of ATR, ERCC1, TOP2A, and ABCB1 genes were determined by the RT-PCR method. Biochemical parameters were also examined. The interaction of proteins with other proteins was investigated with the String v11 program. The IC50 values of compounds 1, 2, and 3 obtained after 72 h were 23.10, 8.93, and 1.58 µg/mL, respectively. The results demonstrate that the cytotoxic activity of compound 3 on AGS cancer cells is higher in comparison with other molecules. It was determined that the expression levels of ATR, TOP2A, and ABCB1 genes in compounds 1, 2, and 3 were decreased compared to the control group. In addition, it was determined that ERCC1 gene expression increased in compound 3, decreased in compound 2, and remained unchanged in compound 1 (p < 0.001). In AGS gastric cancer cells, a 64% decrease was detected for GST levels in compound 1, while a 38% decrease in GSH levels in compound 2. In addition, compounds 1–3 were examined at the molecular level with computational techniques and the docking studies revealed 4LN0 as a target protein.

Objectives: Fibromyalgia syndrome (FMS) is a chronic pain syndrome characterized by widespread body pain over a long period, the cause of which is not yet clearly known. FMS patients usually have high pain sensitivity. We aimed to investigate whether rs4148855 and rs2288646 polymorphisms of acid-sensing ion channel 3 ( ASIC3 ), one of the factors contributing to pain, cause a predisposition to FMS in the Turkish population. Methods: ASIC3 gene rs4148855 and rs2288646 polymorphisms in DNA samples obtained from blood samples of 175 patients with FMS and 176 healthy individuals were analyzed by real-time polymerase chain reaction (RT-PCR) using a hydrolysis probe. Statistical data were obtained by chi-square (χ ² ) test and logistic regression analysis. Results: No significant association was found between ASIC3 gene rs4148855 and rs2288646 polymorphisms and the Turkish population’s FMS group and control group (p>0.05). Conclusions: As a result, no significant association was found between the genotype and allele distributions of ASIC3 polymorphism (rs4148855 and rs2288646) in patients with FMS compared to controls in the Turkish population. Further studies are needed to elucidate the relationship between ion channels and FMS to elucidate the mechanisms of FMS.

Moleküllerden hastalığa, biyokimyasal mekanizmalardan geleceğin tıbbına… İnsan vücudu, her an milyarlarca moleküler etkileşimin gerçekleştiği olağanüstü bir biyolojik sistemdir. Hücreler birbirleriyle haberleşir, dokular metabolik sinyaller gönderir, biyolojik sıvılar moleküler mesajlar taşır ve hastalıkların başlangıcından önce hücresel düzeyde sessiz değişimler meydana gelir.Tıbbi Biyokimya: Vücudun Sessiz Kodları, bu görünmeyen moleküler dünyayı sağlık ve hastalık ekseninde ele alıyor. Bu eser; biyokimyasal mekanizmaları yalnızca açıklamakla kalmayıp, onların erken tanı, biyobelirteç geliştirme, hastalık mekanizmalarının aydınlatılması ve yeni tedavi stratejilerinin oluşturulmasındaki rolünü sorgulamaktadır. Çünkü hastalık çoğu zaman klinik olarak görünür hale gelmeden önce moleküler düzeyde konuşmaya başlar. Tıbbi biyokimya, işte bu sessiz dili duyabilme bilimidir. Bu kitap, vücudun moleküler kodlarını çözmek isteyen araştırmacılar, akademisyenler, sağlık profesyonelleri ve biyomedikal bilimlere ilgi duyan herkes için; molekülden hücreye, hücreden organa, organdan hastalığa ve hastalıktan geleceğin tedavilerine uzanan bilimsel bir keşif alanı sunmaktadır.